Eloralintide Lilly’s Amylin Agonist Outperforms Novo’s Cagrilintide at 48 Weeks

Original posted at obesity.news/ on Nov 06, 2025

There are weeks in this journey where the future feels heavy. Where insurance walls feel too high, access feels too small, and the comment section on the socials can’t seem to move past the idea that obesity is all about willpower instead of biology.

And then there are weeks like this. Today is going to be huge for access, so tune into our YouTube at 11:00 eastern. We have an exciting announcement of our own to go with the white house press briefing on MFN.

But there’s already amazing news this morning.

Lilly just announced results for eloralintide, an amylin medicine that works on a completely different hormone system than GLP-1s. Remember, amylin is cosecreted with insulin in the pancreas. Your body releases them together. Insulin helps manage blood sugar, and amylin helps control hunger and fullness. For many of us, that amylin signal has been missing or disregulated for years.

So what happened when scientists restored it?

People lost up to 20% of their body weight in 48 weeks. Compare that to Novo’s Cagrilintide as around 11% after 68 weeks.

Let that land for a second.

20%.

With a non GLP-1 medicine.

That puts eloralintide right up near Zepbound territory. And it did this as monotherapy, meaning by itself. No stacking. No combination. Just this molecule working on a natural fullness pathway the body was always meant to use.

Bit it gets even bigger.

This medicine may not just be a powerful solo option. It can potentially be stacked with GLP-1s in the future. So if someone starts on a GLP-1 and hits a plateau, or cannot push dose due to side effects, imagine adding an amylin therapy and opening up new weight loss potential. Imagine having two natural hormone systems working together the way the body originally designed them to.

For years we were stuck in such a lonely place, fighting broken biology with shame, white knuckling intense hunger cues brought on by hormonal dysregulation. Today feels like a door cracking open to a world where obesity medicine will finally start to match the complexity of the disease.

A world where:

• One pathway is not your only chance

• If you cannot tolerate a GLP-1, you still have real hope

• Combination therapy becomes standard care, not wishful thinking

This is what it looks like when we stop blaming patients and start treating physiology.

This is what it looks like when science refuses to settle.

This is what it looks like when a community demands better.

If you have ever sat in a parking lot before a doctor appointment, rehearsing your symptoms because you know if you aren’t clear, it will all be chalked up to your weight… These moments are a glimmer of hope.

The toolbox is expanding. The future is widening. And we are not done yet.

Drop a comment:

Would you want this as a primary therapy, or would you want to stack it with a GLP-1 if insurance allowed it.

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe